Related Experiment Video
Updated: Jun 6, 2025
07:39
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.5K
Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review
Hendri Susilo1,2, Fan Maitri Aldian3, Citrawati Dyah Kencono Wungu4,5
1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga Surabaya, Indonesia.
European Cardiology
|November 26, 2024
Summary
Levosimendan offers a promising treatment for cardiogenic shock (CS), improving survival and hemodynamics without increasing myocardial oxygen demand. This review highlights its advantages over traditional inotropes for managing CS.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiogenic shock (CS) is a life-threatening condition with high mortality.
- Current management strategies for CS face significant challenges, necessitating novel therapeutic approaches.
Purpose of the Study:
- To comprehensively review the efficacy and safety of levosimendan in managing cardiogenic shock.
- To compare levosimendan with traditional inotropic agents used in CS treatment.
Main Methods:
- Systematic review and synthesis of evidence from numerous studies.
- Comparative analysis of levosimendan against enoximone, dobutamine, dopamine, and norepinephrine.
- Critical assessment of safety profiles and adverse effects.
Main Results:
- Levosimendan enhances myocardial contractility without increasing oxygen demand, a unique mechanism in CS management.
- Comparative studies indicate levosimendan's superiority in improving survival rates and hemodynamic parameters.
- Levosimendan demonstrated a reduction in CS complications compared to traditional agents.
Conclusions:
- Levosimendan represents a valuable therapeutic option for cardiogenic shock.
- The drug shows potential for improved patient outcomes in CS management.
- Its unique mechanism and demonstrated benefits support its role in clinical practice.
Keywords:
Levosimendanadenosine triphosphate-dependent potassium channel openercalcium sensitisercardiogenic shockcardiovascular diseaseMore Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
01:26Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:22Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
01:24Blood Pressure Imbalances and Circulatory Shock
753
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
753
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K